pmc logo image
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)
Andrew F Shorr, David R Nelson, Duncan LA Wyncoll, Konrad Reinhart, Frank Brunkhorst, George Matthew Vail, Jonathan Janes
Crit Care. 2008; 12(2): R45. Published online 2008 April 4. doi: 10.1186/cc6854
PMCID:
PMC2447591
Abstract Full Text PDF–328K
 Is Cited by the Following 4 Articles in this Archive:
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)
Andrew F Shorr, Jonathan M Janes, Antonio Artigas, Jyrki Tenhunen, Duncan LA Wyncoll, Emmanuelle Mercier, Bruno Francois, Jean-Louis Vincent, Burkhard Vangerow, Darell Heiselman, Amy G Leishman, Yajun E Zhu, Konrad Reinhart
Crit Care. 2010; 14(6): R229. Published online 2010 December 21. doi: 10.1186/cc9382
PMCID:
PMC3219981
Abstract Full Text PDF–846K Supplementary Material
Activated protein C in severe acute pancreatitis without sepsis? Not just yet ...
Manu Shankar-Hari, Duncan Wyncoll
Crit Care. 2010; 14(4): 188. Published online 2010 August 9. doi: 10.1186/cc9190
PMCID:
PMC2945109
Abstract Full Text PDF–118K
Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies
Laith Altaweel, Daniel Sweeney, Xizhong Cui, Amisha Barochia, Charles Natanson, Peter Q Eichacker
Biologics. 2009; 3: 391–406. Published online 2009 September 15.
PMCID:
PMC2747338
Abstract Full Text PDF–439K
Protein C as a surrogate end-point for clinical trials of sepsis
Kathleen D Liu, Michael A Matthay
Crit Care. 2008; 12(2): 139. Published online 2008 April 24. doi: 10.1186/cc6859
PMCID:
PMC2447596
Abstract Full Text PDF–41K
You are here: NCBI > Literature > PubMed Central
Write to the Help Desk